Skip to main content
Premium Trial:

Request an Annual Quote

Accelrys Reports 2 Percent Increase in Fiscal Q2 Revenues, Net Income Declines

NEW YORK (GenomeWeb News) – Accelrys today reported a 2 percent uptick in revenues for the second quarter of its 2009 fiscal year, accompanied by a 25 percent dip in net profit for the period.
The scientific software firm’s revenue for the quarter ended Sept. 30, 2008, rose slightly to $20.1 million from $19.7 million for the same quarter of the previous year.
Product development costs declined 11 percent to $3.8 million from $4.3 million in the third quarter of 2007, while sales and marketing costs rose 15 percent to $8.2 million from $7.1 million.
Net income fell to $1.2 million, or $.04 per share, from $1.6 million, or $.06 per share, for the same quarter of the previous year.
As of Sept. 30, Accelrys had $70.3 million in cash, cash equivalents, and marketable securities.
Mark Emkjer, president and CEO of Accelrys, said in a statement that the company’s financial results were “in line with our expectations.”

Filed under

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.